已收盘 12-19 16:00:00 美东时间
0.000
0.00%
Guggenheim analyst Brad Canino downgrades Black Diamond Therapeutic (NASDAQ:BDTX) from Buy to Neutral.
12-04 21:48
Black Diamond Therapeutics CEO Mark Velleca to participate in a fireside chat at Jefferies Global Healthcare Conference on June 4, 2025, alongside hosting investor meetings. Webcast available on the company’s website.
05-29 12:00
BDTX: 54% | Black Diamond Therapeutics shares are trading higher after the company announced initial Phase 2 data demonstrating encouraging clinical responses and durability of BDTX-1535 in patients with
2024-09-23 20:10
Treatment data were analyzed from 3,276 cases of patients with newly diagnosed EGFR mutant NSCLC from Guardant Health Analyses of patients with non-classical EGFR mutations reveal that the majority receive frontline
2024-09-16 16:40
HC Wainwright & Co. analyst Robert Burns reiterates Black Diamond Therapeutic (NASDAQ:BDTX) with a Buy and maintains $11 price target.
2024-09-04 19:28
Black Diamond Therapeutic's (NYSE:BDTX) short percent of float has fallen 6.83% since its last report. The company recently reported that it has 4.44 million shares sold short, which is 13.23% of all regular shares that are available for trading. Based on its trading volume, it would take traders 13...
2024-08-22 21:15